Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy

Cancer Science

Volumn 104, Issue 1, 2013, Pages 78-84

  Kubo, Toshio ^a   Takigawa, Nagio ^b   Osawa, Masahiro ^a   Harada, Daijiro ^a   Ninomiya, Takashi ^a   Ochi, Nobuaki ^a   Ichihara, Eiki ^a   Yamane, Hiromichi ^b   Tanimoto, Mitsune ^a   Kiura, Katsuyuki ^c  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; AMRUBICIN; CD133 ANTIGEN; CISPLATIN; ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE; CELL PROLIFERATION; CELL SUBPOPULATION; CELL SURFACE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTHRACYCLINES; ANTIGENS, CD; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PACLITAXEL; PEPTIDES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, MESSENGER; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84872275911     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12045     Document Type: Article

References (27)

1. Fukuoka M, Masuda N, Matsui K et al. Combination chemotherapy with or without radiation therapy in small cell lung cancer. An analysis of a 5-year follow-up. Cancer 1990; 65: 1678-84.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-8.
3. Zeppernick F, Ahmadi R, Campos B et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008; 1: 123-9.
4. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51.
5. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-5.
6. Haraguchi N, Ishii H, Mimori K et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010; 120: 3326-39.
7. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 4827-33.
8. Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-14.
9. Peacock CD, Watkins DN. Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol 2008; 26: 2883-9.
10. Bertolini G, Roz L, Perego P et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009; 106: 16 281-16.
11. Meng X, Li M, Wang X, Wang Y, Ma D. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci 2009; 100: 1040-6.
12. Gutova M, Najbauer J, Gevorgyan A et al. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS ONE 2007; 2: e243.
13. Romer J, Nielsen BS, Ploug M. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 2004; 10: 2359-76.
14. Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 2008; 14: 5649-55.
15. Onoda S, Masuda N, Seto T et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: thoracic Oncology Research Group Study 0301. J Clin Oncol 2006; 24: 5448-53.
16. Yamane H, Kiura K, Tabata M et al. Small cell lung cancer can express CD34 antigen. Anticancer Res 1997; 17: 3627-32.
17. Miyamoto H. Establishment and characterization of an adriamycin-resistant subline of human small cell lung cancer cells. Acta Med Okayama 1986; 40: 65-73.
18. Tsuchida T, Yamane H, Ochi N et al. Cytotoxicity of activated natural killer cells and expression of adhesion molecules in small-cell lung cancer. Anticancer Res 2012; 32: 887-92.
19. Moritaka T, Kiura K, Ueoka H et al. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids. Anticancer Res 1998; 18: 927-33.
20. Chikamori M, Takigawa N, Kiura K et al. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line. Anticancer Res 2004; 24: 3911-6.
21. Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Kimura I. Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Med Okayama 1992; 46: 203-12.
22. Tani N, Yabuki M, Komuro S, Kanamaru H. Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica 2005; 35: 1121-33.
23. Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Kimura I. Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines. Acta Med Okayama 1992; 46: 249-56.
24. Chen YC, Hsu HS, Chen YW et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE 2008; 9: e2637.
25. Jäeger W. Classical resistance mechanisms. Int J Clin Pharmacol Ther 2009; 47: 46-8.
26. Galluzzi L, Senovilla L, Vitale I et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869-83.
27. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 2010; 15: 950-8.